BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Furuse J. Sorafenib for the treatment of unresectable hepatocellular carcinoma. Biologics 2008;2:779-88. [PMID: 19707458 DOI: 10.2147/btt.s3410] [Cited by in Crossref: 3] [Cited by in F6Publishing: 22] [Article Influence: 0.3] [Reference Citation Analysis]
Number Citing Articles
1 Wang C, Lu Y, Wang H, Gao X, Bai W, Qu J, Xu G, Zhang Z, Zeng Z, Zhou L, An L, Lv J, Yang Y. Transarterial chemoembolization with/without cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma. Exp Ther Med 2012;4:188-96. [PMID: 23139708 DOI: 10.3892/etm.2012.569] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
2 Yang Y, Lu Y, Wang C, Bai W, Qu J, Chen Y, Chang X, An L, Zhou L, Zeng Z, Lou M, Lv J. Cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma. Exp Ther Med. 2012;3:171-180. [PMID: 22969864 DOI: 10.3892/etm.2011.398] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
3 Wang R, Lin N, Mao B, Wu Q. The efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma: a meta-analysis based on 40 cohorts incorporating 3697 individuals. J Cancer Res Clin Oncol 2021. [PMID: 34297207 DOI: 10.1007/s00432-021-03716-1] [Reference Citation Analysis]
4 Yamanaka K, Hatano E, Kitamura K, Iida T, Ishii T, Machimito T, Taura K, Yasuchika K, Isoda H, Shibata T. Early evaluation of transcatheter arterial chemoembolization-refractory hepatocellular carcinoma. J Gastroenterol. 2012;47:343-346. [PMID: 22183859 DOI: 10.1007/s00535-011-0511-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
5 Oyama K, Koda M, Sugihara T, Kishina M, Miyoshi K, Okamoto T, Hodotsuka M, Fujise Y, Matono T, Tokunaga S, Okamoto K, Hosho K, Okano J, Murawaki Y. Rapid and early α-fetoprotein and des-γ-carboxy prothrombin responses to initial arterial infusion chemotherapy predict treatment outcomes of advanced hepatocellular carcinoma. Mol Clin Oncol 2015;3:655-62. [PMID: 26137283 DOI: 10.3892/mco.2015.523] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
6 Yang Y, Lu Y, Wang C, Bai W, Qu J, Chen Y, Chang X, An L, Zhou L, Zeng Z. Cryotherapy is associated with improved clinical outcomes of Sorafenib therapy for advanced hepatocellular carcinoma. Cell Biochem Biophys. 2012;63:159-169. [PMID: 22477032 DOI: 10.1007/s12013-012-9353-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
7 Kim J, Mirando AC, Popel AS, Green JJ. Gene delivery nanoparticles to modulate angiogenesis. Adv Drug Deliv Rev 2017;119:20-43. [PMID: 27913120 DOI: 10.1016/j.addr.2016.11.003] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 6.3] [Reference Citation Analysis]
8 Liang Y, Chen J, Yu Q, Ji T, Zhang B, Xu J, Dai Y, Xie Y, Lin H, Liang X. Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma. Cancer Med. 2017;6:2787-2795. [PMID: 29030911 DOI: 10.1002/cam4.1228] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
9 Wecksler AT, Hwang SH, Liu JY, Wettersten HI, Morisseau C, Wu J, Weiss RH, Hammock BD. Biological evaluation of a novel sorafenib analogue, t-CUPM. Cancer Chemother Pharmacol 2015;75:161-71. [PMID: 25413440 DOI: 10.1007/s00280-014-2626-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
10 Chen JY, Chen YJ, Yen CJ, Chen WS, Huang WC. HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3. Oncotarget 2016;7:473-89. [PMID: 26595522 DOI: 10.18632/oncotarget.6337] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
11 Ye SL, Chen X, Yang J, Bie P, Zhang S, Liu F, Liu L, Zhou J, Dou K, Hao C, Shao G, Xia Q, Chen Y, Yang J, Deng X, Liu Y, Yuan Y, Fu Z, Nakajima K, Yip CS, Lu Z. Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON study. Oncotarget 2016;7:6639-48. [PMID: 26735891 DOI: 10.18632/oncotarget.6781] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
12 Nair SV, Hettihewa M, Rupasinghe HP. Apoptotic and inhibitory effects on cell proliferation of hepatocellular carcinoma HepG2 cells by methanol leaf extract of Costus speciosus. Biomed Res Int 2014;2014:637098. [PMID: 24818148 DOI: 10.1155/2014/637098] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
13 Hiramine Y, Uto H, Imamura Y, Tabu K, Baba Y, Hiwaki T, Sho Y, Tahara K, Higashi H, Tamai T. Sorafenib and hepatic arterial infusion chemotherapy for unresectable advanced hepatocellular carcinoma: A comparative study. Exp Ther Med. 2011;2:433-441. [PMID: 22977522 DOI: 10.3892/etm.2011.237] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
14 Bahman AA, Abaza MSI, Khoushiash SI, Al-Attiyah RJ. Sequence‑dependent effect of sorafenib in combination with natural phenolic compounds on hepatic cancer cells and the possible mechanism of action. Int J Mol Med 2018;42:1695-715. [PMID: 29901131 DOI: 10.3892/ijmm.2018.3725] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
15 Baghy K, Horváth Z, Regős E, Kiss K, Schaff Z, Iozzo RV, Kovalszky I. Decorin interferes with platelet-derived growth factor receptor signaling in experimental hepatocarcinogenesis. FEBS J 2013;280:2150-64. [PMID: 23448253 DOI: 10.1111/febs.12215] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 4.4] [Reference Citation Analysis]
16 Li J, Zhang F, Yang J, Zhang Y, Wang Y, Fan W, Huang Y, Wang W, Ran H, Ke S. Combination of individualized local control and target-specific agent to improve unresectable liver cancer managements: a matched case-control study. Target Oncol 2015;10:287-95. [PMID: 25293575 DOI: 10.1007/s11523-014-0338-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
17 Zhou K, Nguyen R, Qiao L, George J. Single cell RNA-seq analysis identifies a noncoding RNA mediating resistance to sorafenib treatment in HCC. Mol Cancer 2022;21:6. [PMID: 34980140 DOI: 10.1186/s12943-021-01473-w] [Reference Citation Analysis]
18 Yao Q, Zhang H, Xiong B, Zheng C. Combination of sorafenib and TACE inhibits portal vein invasion for intermediate stage HCC: a single center retrospective controlled study. Oncotarget 2017;8:79012-22. [PMID: 29108283 DOI: 10.18632/oncotarget.20745] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
19 Ni H, Yang M, Guo Z, Zhang T. Sorafenib combined with cryoablation to treat unresectable hepatocellular carcinoma. Chin J Cancer Res 2011;23:188-93. [PMID: 23467380 DOI: 10.1007/s11670-011-0188-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
20 Son Y, Shin NR, Kim SH, Park SC, Lee HJ. Fibrinogen-Like Protein 1 Modulates Sorafenib Resistance in Human Hepatocellular Carcinoma Cells. Int J Mol Sci 2021;22:5330. [PMID: 34069373 DOI: 10.3390/ijms22105330] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Mohamed A, Chenna A, Abdelfatah M, Sanjay J, Mohammad MK, Saber I, Kauh J, Elhammali B, Kaseb A. Microvessel density analysis in patients with viral hepatitis-related hepatocellular carcinoma. J Gastrointest Cancer 2015;46:104-8. [PMID: 25645584 DOI: 10.1007/s12029-015-9684-5] [Reference Citation Analysis]
22 Ying ZL, Li XJ, Dang H, Wang F, Xu XY. Saikosaponin-d affects the differentiation, maturation and function of monocyte-derived dendritic cells. Exp Ther Med. 2014;7:1354-1358. [PMID: 24940438 DOI: 10.3892/etm] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
23 Wang D, Jia W, Wang Z, Wen T, Ding W, Xia F, Zhang L, Wu F, Peng T, Liu B, Zhou C, Zheng Q, Miao X, Peng J, Huang Z, Dou K. Retrospective analysis of sorafenib efficacy and safety in Chinese patients with high recurrence rate of post-hepatic carcinectomy. Onco Targets Ther 2019;12:5779-91. [PMID: 31410023 DOI: 10.2147/OTT.S168447] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]